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CGG repeat expansion >200 within FMR1, termed full mutation (FM), has been associated 
with promoter methylation, consequent silencing of gene expression and fragile X syndrome 
(FXS) – a common cause of intellectual disability and co-morbid autism. Unmethylated 
premutation (55 to 199 repeats) and FM alleles have been associated with fragile X related 
tremor/ataxia syndrome (FXTAS), a late onset neurodegenerative disorder. Here we present 
a 33 year old male with FXS, with white matter changes and progressive deterioration in gait 
with cerebellar signs consistent with probable FXTAS; there was no evidence of any other 
cerebellar pathology. We show that he has tissue mosaicism in blood, saliva and buccal 
samples for the size and methylation of his expanded alleles and a de novo, unmethylated 
microdeletion. This microdeletion involves a ~80bp sequence in the FMR1 promoter as well 
as complete loss of the CGG repeat in a proportion of cells. Despite FMR1 mRNA levels in 
blood within the normal range, the methylation and CGG sizing results are consistent with 
the diagnosis of concurrent FXS and probable FXTAS. The demonstrated presence of 
unmethylated FM alleles would explain the manifestation of milder than expected cognitive 
and behavioural impairments and early onset of cerebellar ataxia. Our case suggests that 
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Fragile X syndrome (FXS) is the most common heritable form of intellectual disability 
and autism, found in 1 in 4000 in males and 1 in 8000 in females in the general populaiton, 
reviewed in [Hagerman et al., 2009]. FXS usually results from CGG repeat expansion > 200, 
termed ‘full mutation’ (FM), subsequent methylation of the regulatory regions and silencing 
of the FMR1 gene located on the X chromosome [Godler et al., 2010]. Fragile X associated 
tremor/ataxia syndrome (FXTAS) is a ‘late-onset’ neurodegenerative disorder affecting 
carriers of the CGG expansion between 55 and 199 repeats, termed premutation 
(PM)[Jacquemont et al., 2004]. These PM alleles have estimated frequencies of 1 in 468 
males and 1 in 151 females in the general population, and are associated with over-
expression of the FMR1 gene and toxicity from excessive RNA production leading to cell 
death contributing to FXTAS pathology, reviewed in [Hagerman et al., 2009]. Probable FXTAS 
has also been described in FM males with an unmethylated FMR1 promoter region (UFM), 
resulting in active FMR1 gene and IQ greater than 70 [Loesch et al., 2012; Santa Maria et al., 
2013]. Here we present a case of one FXS male with clinical features consistent with 
probable FXTAS first manifesting in his early 30s. We show that he has unmethylated as well 
as methylated FM alleles, tissue mosaicism for the size of his expanded FMR1 alleles and a 
de novo microdeletion in the FMR1 promoter involving complete loss of the CGG expansion. 
CLINICAL REPORT 
Clinical History and Sample Processing 
At 5 years of age, this male was diagnosed with FXS based on morphological features 
and cytogenetic testing showing 40% of cells expressing the Xq27.3 fragile site. At 33 years 
of age he was referred to the neurology service for assessment of progressive unsteadiness 
developing over 18 months. There was no accompanying weakness or sensory disturbance. 
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His physical examination revealed mildly increased tone in all limbs, no tremor, mild 
symmetrical proximal weakness in the lower limbs and moderate midline ataxia.  
20 ml of peripheral blood was collected in EDTA tubes for CGG sizing, methylation 
and FMR1 mRNA analyses. Buccal samples were also collected using the Master Amp Buccal 
Swab Brush kit (Epicentre technologies, USA). DNA was extracted from 15ml of blood and 
from buccal brush samples using the NucleoSpin®Tissue genomic DNA extraction kit 
(Machery-Nagel, Germany). 5 ml of blood was used for peripheral blood mononuclear cell 
(PBMC) isolation using Ficoll gradient separation [Loesch et al., 2011]. RNA was extracted 
from the isolated PBMCs using RNeasy kit (Qiagen Global) as per the manufacturer’s 
instructions. 
FMR1 Methylation, mRNA, CGG and Proximal Region sizing/copy number changes.  
CGG repeat sizing in all samples was performed using polymerase chain reaction 
(PCR) as previously described [Khaniani et al., 2008]. The AmplideX™ FMR1 PCR Kit was used 
to perform CGG sizing on and determine mean methylation at two HpaII sites, 5’ and 3’ of 
the CGG expansion using blood DNA as per manufacturer’s instructions (Asuragen, Texas, 
USA). Methylation sensitive Southern blot was used to determine CGG size and methylation 
of the FMR1 CpG island 5’ of the CGG expansion. Appropriate normal CGG size, PM and FM 
DNA samples used in a previous publication [Godler et al., 2010] were included as 
methylation controls. Seven to 9g of DNA were digested with either methylation sensitive 
enzyme combination of NruI/HindIII or EagI/ EcoRI or PstI which is not sensitive to 
methylation changes (Figure 1). P32 labelled Pfxa3a probe (PCR Dig Synthesis kit; Roche 
Diagnostics Global) was used to detect FMR1 alleles by autoradiography as previously 
described [Godler et al., 2010], with the PS8 control probe used for the PstI digestion. 
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FREE1 and FREE2 PCR products were synthesised using primers and conditions 
previously described [Godler et al., 2010], and sized using capillary electrophoresis to rule 
out presence of the deletion at the 5’ epigenetic boundary of the FMR1 promoter and the 
exon1/intron 1 boundary at the 3’end of the FMR1 promoter (Figure 1). The Sequenom 
MALDI-TOF MS EpiTYPER system (Sequenom, USA) was used to analyse mean methylation 
of the FREE2 region located 3’ of the CGG repeat in blood, buccal and saliva samples, as 
previously described  [Godler et al., 2010]. Two and a half million probe based microarray 
analysis was performed using blood DNA, to rule out large pathogenic copy number changes 
other than within FMR1, as well as to examine copy number changes of SNPs proximal to 
the CGG expansion, as previously described [Motoike et al., 2014]. FMR1 mRNA was 
reverse-transcribed in two separate cDNA reactions and each cDNA sample was analysed 
using real time-PCR reactions, as previously described [Loesch et al., 2011].  
Clinical assessments 
Blood tests, including thyroid function tests, vitamin B12 and autoimmune antibody 
panel, were within normal limits. Nerve conduction studies performed at the time did not 
reveal any evidence of peripheral neuropathy. MRI of his brain and spine revealed normal 
cerebellum without white matter lesions in the middle cerebellar peduncles and diffuse but 
non-specific T2 hyperintensities in the supratentorial cerebral white matter (Figure 2) that 
were stable on repeat imaging 9 months later despite development of spastic paraparesis in 
the intervening period. These radiological findings and the gait ataxia met the diagnostic 
criteria for probable FXTAS [Loesch et al., 2005]. He was referred to a clinical geneticist to 
explore the possible presence of PM and unmethylated FM alleles. 
At 35 years of age formal psychological assessment for this male was also performed. 
The Wechsler Adult Intelligence Scale (WAIS-IV) [D. 2008] showed that his cognitive ability 
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was in the ‘Extremely Low’ range with a full scale IQ of 51 (percentile rank 0.1; 95% 
confidence interval: 48-56). His WAIS-IV indexes scores did not differ significantly and were 
all within the ‘Extremely Low’ range. The Autism Diagnostic Observation Schedule – Second 
Edition (ADOS-2) [Lord 2012] assessment revealed some behavioural features consistent 
with autism spectrum disorder including deficits in communication skills, reciprocal social 
interaction and social-emotional reciprocity that appeared to be separate from his 
impairment in verbal communication and general intellectual function. However, he did not 
satisfy the diagnostic criteria for autism spectrum disorder as per Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (American Psychiatric Association 2013). 
Testing for Causes of Ataxia 
Friedreich's ataxia (FA) and Spinocerebellar Ataxias (SCA) repeat regions were 
examined using PCR and gel electrophoresis, as previously described protocols [Biros et al., 
1998; Campuzano et al., 1996]. Furthermore, omni2.5-8 microarray was used to identify no 
copy number changes associated with whole exon deletions/duplications in the known 
ataxia or neuropathy genes, based on average probe density [Motoike et al., 2014].  
RESULTS AND DISCUSSION 
CGG sizing and detection of microdeletion 
Southern blot FMR1 CpG island methylation analysis in blood showed unmethylated 
fragments between 2.5 and 4.5 Kb for NruI/HindIII digestion and 2.6 to 4.4 Kb for EagI/EcoRI 
digestion (Figure 1A). There were also methylated fragments between 4.7 and 6.5 Kb for 
NruI/HindIII digestion and 5.2 and 6.1 Kb for EagI/EcoRI digestion. For the PstI digestion 
(that was not methylation sensitive) the expanded alleles ranged in size from 1.63kb to 
2.83Kb. Together the two methylation sensitive digestions, NruI/HindIII and EagI/EcoRI, 
suggested presence of unmethylated and methylated FM alleles ranging in size from 463 to 
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846 CGG repeats (Figure 1 A and B). The presence of FM alleles within this size range was 
further confirmed by the PstI digestion based Southern blot in buccal DNA (Figure 1C).  
All three digests followed by Southern blot also detected a fragment that was ~0.2Kb 
smaller than that in normal controls. This smaller allele was exclusively unmethylated and 
absent from the patient’s mother’s blood, the mother herself being a mosaic of PM and FM 
alleles (Figure 1C). The absence of the smaller allele in the mother suggested that the pro-
band is mosaic for a de novo microdeletion and FM expansion. As the same smaller band 
was detected in all 3 digests, a microdeletion would have to be located within PstI/PstI 
fragment and also within the overlapping NruI/HindIII and EagI/EcoRI fragments (Figure 1 
A). Within this PstI fragment, the microdeletion is unlikely to occur within the exon 1 or 
intron 1 of FMR1 as microarray SNP copy number proximal to the repeat within intron 1 and 
PCR amplicon sizing of the FREE2 region on the exon1/intron 1 boundary were both 
completely normal (Figure 1 A and D). In this context, it is important to note that microarray 
SNP analysis did not identify any pathogenic variants elsewhere in the genome and the 
amplicon size of FREE1 located at the 5’end of the FMR1 promoter was also completely 
normal (Figure 1 D).  This microdeletion must therefore involve complete loss of the CGG 
expansion together with a proximal binding site of one of the Amplidex PCR primers as the 
microdeletion was not detected using AmplideX PCR (Figure 1 E).  Furthermore, this 
microdeletion must include loss of the Amplidex primer binding site located within the CpG 
island located ~87 bp 5’of the CGG repeat, as in a previous case [Schmucker et al., 1996].  
Discordance between Southern blot and AmplideX PCR CGG sizing. 
Unmethylated PM alleles of ~70 repeats were detected by Southern blot following 
NruI/HindIII and EagI/EcoRI digests, as indicated by the lower points of smears of ~2.9Kb 
and 3.0Kb in size, respectively (Fig 1B). However, PM alleles were not detected using 
 Hwang et al.  
Page: 8 
 
AmplideX PCR or standard sizing PCR [Khaniani et al., 2008], the latter having primer binding 
sites proximal to those of AmplideX. Only partially methylated FM size alleles were detected 
using AmplideX PCR. This discordance is unlikely to be due to the sizing imprecision of our 
Southern blot analyses ( +/-30 CGG repeats) as an extended Southern blot smear is still 
within the PM range. An alternative explanation could be microdeletion involving both a 
portion of CGG repeat and the Amplidex primer binding site, similar to the the smaller 
~2.5kb Southern blot band that was also undetected using AmplideX PCR.  
Discordance between Southern blot and Amplidex PCR methylation analysis. 
Two prominent FM allele types were detected in blood, buccal and saliva DNA using 
Amplidex PCR (Figure 2E). These alleles were also identified by Southern blot after 
NruI/HindIII, EagI/EcoRI and PstI digests. However, there was significant discordance 
between the methylation percentage estimated by Southern blot following NruI/HindIII and 
EagI/EcoRI digestion and that by AmplideX analysis of two HpaII sites located either side of 
the expansion (Figure 1). The mean Amplidex HpaII methylation estimate was ~60% in blood 
and saliva and 94% in buccal DNA (Figure 1E). In contrast, NruI and EagI methylation values 
were only 11% and 12%, respectively for Southern blot (100 X density of all methylated 
bands/total of unmethylated and methylated bands) (Figure 1B). If the density of the ~2.5Kb 
microdeletion band is not taken out of this calculation (as AmplideX does not detect it), NruI 
and EagI methylation values increase to 28% and 26%, respectively. This discordance could 
be because sizing and methylation analysis of all alleles that also have the microdeletion 
with the AmlideX primer binding sites (exclusively unmethylated by southern blot) being 
missed, leading to over-estimation of methylation by AmplideX for this case. 
FREE2 Methylation, FMR1 mRNA Analyses and Testing for Other Genetic Causes of Ataxia 
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Increase in FREE2 methylation has been previously linked to FMR1 protein (FMRP) 
deficiency and the severity of cognitive impairment in FM males and females with FXS 
[Godler et al., 2012]. In this male, blood and saliva showed mean FREE2 methylation output 
ratio (MOR) of ~0.4, while buccal samples showed MOR of ~0.45 (Figure 2C). Interestingly 
the methylation values remained un-changed between blood and saliva samples collected 
1.5 years apart. All MOR values were above those of normal allele and PM methylation 
ranges in males but were below the FREE2 methylation range for typical FXS males carrying 
only FM alleles. These MOR values suggest that approximately 40% of leukocytes and ~45% 
of epithelial (buccal) cells have methylated alleles. This is consistent with the patient’s 
milder cognitive and behavioural impairments compared to those of ‘typical FXS’ males 
carrying only highly methylated FM alleles. While unmethylated FM alleles have been 
associated with overexpression of FMR1 mRNA and increased risk of FXTAS [Loesch et al., 
2012], it is not clear if the PM alleles with the proposed microdeletion could also contribute 
to the probable FXTAS phenotype observed in this patient (Figure 1).  
Analysis of FMR1 transcription in PBMCs revealed an mRNA level of 0.97 arbitrary 
units which is within the normal male expression range, above the levels observed for FM 
only and PM/FM mosaic males with the typical FXS phenotype (Figure 2D). This is consistent 
with FREE2 methylation results where more than half of all cells would have an 
unmethylated promoter, overexpress FMR1 at twice the normal level, as previously 
described [Loesch et al., 2011; Loesch et al., 2012], but overall would show normal FMR1 
mRNA levels because the remaining cells would have a completely methylated FMR1 
promoter with no FMR1 mRNA expression.  Testing for other causes of ataxia excluded 
Friedrich’s ataxia, spinocerebellar ataxias type 1, 2, 3, 6 and 7 by PCR; and copy number 
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changes associated with common peripheral neuropathies such as CMT1A and HNPP by the 
genome-wide array testing.  
CONCLUSION 
This is the first reported case of an FXS male showing white matter changes and 
progressive deterioration in gait with cerebellar signs, meeting the diagnostic criteria of 
probable FXTAS at 30 years of age. Our patient has cerebellar dysfunction with no evidence 
of any other cerebellar pathology and has molecular features of mosaicism for CGG repeat 
size, a de-novo microduplication within the FMR1 promoter for a proportion of cells, 
methylation mosaicism amongst different CpG sites and tissue types and UFM alleles that 
are consistent with FXTAS clinically manifesting concurrently with FXS. Our case adds to the 
expanding and evolving clinical and genetic profile of FXTAS and FXS, suggests that 
assessment for FXTAS may need to be broadened to detect males with partially methylated 
FM alleles and highlights the need for comprehensive testing to fully describe the range of 
underlying molecular pathologies.   
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Figure 1. Sizing of the CGG repeat and proximal regions using Southern blot and PCR. (A) 
Organization of the FMR1 5’ region  including the CGG expansion (sequence numbering 
from GenBank L29074 L38501) in relation to FMR1 and ASFMR1  transcription start sites, 
Fragile X Related Epigenetic Elements 1 and 2 (FREE1 and FREE2), the FMR1 CpG island and 
methylation sensitive restriction sites and corresponding fragments analysed,  as well as the  
Pfxa3 probe used in routine fragile X Southern blot testing, two HpaII sites  targeted by 
Amplidex methylation PCR (red arrows indicate primer binding sites). Purple arrows indicate 
standard CGG PCR binding sites as previously described [Khaniani et al., 2008]. Locations of 
probes targeting two single nucleotide polymorphisms from the whole genome 2.5 million 
probe microarray analysis [Motoike et al., 2014] are indicated by black arrows labelled as 
OmniSNP#3 and SNP#5.  (B) Methylation sensitive Southern blot analysis of the NruI and 
EagI restriction sites within FMR1 CpG island. The blood DNA sample in question from the 
FXS male suspected of FXTAS is in lanes 3 and 6 with broken blue lines indicating positive 
bands in these samples. Comparator DNA, sized using standard CGG sizing PCR, from 
healthy control males is in lanes 2 and 5, and from an affected FM female in lanes 1 and 4. 
The 5.1Kb band size represents ~46 CGG repeat methylated alleles in the NruI/HindIII digest. 
The 4.9Kb band size represents ~30 CGG repeat methylated alleles in the EagI/EcoRI digest. 
All larger bands are methylated and labelled M.  All smaller bands are unmethylated, and 
labelled UM. (C) Southern blot analysis of the PstI restriction sites (not methylation 
sensitive).  The buccal DNA sample in question from the FXS male suspected of FXTAS is in 
lane 1; his mother’s blood DNA is in lane 2; broken blue lines indicate positive bands in 
these samples. Comparator DNA sized using standard CGG sizing PCR from two premutation 
females (90 and 101 CGG repeats by PCR) are in lanes 3 and 4. Male and female healthy 
control DNA are in lanes 5 and 6. (D) Capillary electrophoresis sizing of FREE1 and FREE2 PCR 
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products synthesised using primers and conditions previously described [Godler et al., 
2010]. (E) AmplideX PCR targeting methylation of two HpaII sites from capillary 
electrophoresis of the DNA from the blood, buccal and saliva of the male case in question.  
Note: Presence of positive FM alleles with methylated HpaII sites and the control digestion 
(HpaII methylation independent) are indicated capillary electrophoresis signatures in green 
and blue, respectively.  
 
Figure 2. Magnetic Resonance Imaging of the Brain, FMR1 mRNA expression and FREE2 
methylation in peripheral tissues. (A) T2 weighted image of the brain. Note white matter 
changes bilaterally but more pronounced in the deep white matter of right hemisphere. 
These changes would not be expected to be seen in a normal 33 year old. (B) FMR1 mRNA 
assessed using real-time PCR relative standard curve method. Note: the error bars for 
reference ranges represent 2 standard deviations from the FMR1 mRNA levels in RNA from 
peripheral blood mononuclear cells (PBMCs) of 19 male controls (CGG<44) co-run with the 
RNA from the male case in question. RNA  from PBMCs of two FXS  affected males, FXS#1 
PM/FM mosaic (71, 213-480 CGGs; developmental delay; no formal cognitive testing) and  
FXS#2 FM only (543-633 CGGs; FSIQ 44; VIQ 50; PIQ 54) were also included. (C)  Mean 
methylation output ratio of CpG sites located within the FREE2 region assessed using 
MALDI-TOF MS. Case’s blood and buccal samples were collected at two time points 1.5 
years apart. Note: the error bars for reference ranges represent  2 standard deviations from 
the mean FREE2 methylation in blood of 17 male controls (CGG<44); 39 PM males (56-170 
CGGs); 65 FM males with typical FXS (213-2000 CGGs) and 4 atypical ‘high functioning’ FM 
males unmethylated by Southern blot (UFM)  (CGG 200-637 CGG). The reference samples 
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were co-run with DNA from FXS male case suspected of FXTAS from blood, buccal and saliva 
samples in question.  
  
 
